Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 5Carcinoma, Ovarian Epithelial 4Peritoneal Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma 3Stomach Neoplasms 2Neoplasms 2Neoplasms, Glandular and Epithelial 1EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast) 1Ascites 1Adenocarcinoma 1

Interventions

napabucasin 3Irinotecan 3Gemcitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3entinostat 2Paclitaxel 2Leucovorin 2Fluorouracil 2sipuleucel-T 1pralsetinib 1pembrolizumab 1luprolide acetate gel depot 1lenvatinib 1interferon gamma-1b 1ficlatuzumab 1catumaxomab 1Vaccines 1Papillomavirus Vaccines 1Oncolytic Virotherapy 1Ocoxin 1Nivolumab 1Leuprolide 1Interferon-gamma 1Immunotherapy 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Gefitinib 1Filgrastim 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms, Glandular and Epithelial × catumaxomab × Clear all
NCT00326885 2018-10-17

Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites

Neovii Biotech

Phase 2 Completed
32 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Ascites, Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡